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1. Introduction
The advent of high definition endoscopy has transformed the management of pre-malignant
and early malignant diseases of the esophagus and upper gastrointestinal tract. The ability
to view the mucosa in detail whereby the cellular architecture can be viewed has enabled
the endoscopist to make in-vivo histopathological diagnoses, which in turn will direct the
management of the pathology instantly. In this chapter, we describe the various techniques
available from high definition white light endoscopy, through chromoendoscopy and confo‐
cal endomicroscopy. We describe the characteristics and staging of lesions of the esophagus
including Barrett’s esophagus (BE) and associated esophageal adenocarcinoma. Further‐
more, we describe how endoscopy can be used to define Barrett’s and squamous dysplasia.
Finally, we describe the classification and staging of early cancers of the esophagus and ex‐
plore the role of endoscopic ultrasound. We also examine the role of emerging radiological
techniques such as virtual colonography that act as adjuncts to current practice and will no
doubt help to focus the expertise of skilled endoscopists towards interventional endoscopy
rather than routine diagnostic procedures.
Accurate diagnosis and staging of benign and malignant lesions of the esophagus requires
an in-depth understanding of current endoscopic techniques and the latest technology. The
endoscopic optical technology has evolved rapidly in the last decade such that the resolu‐
tion of the ‘CCD” chip is up to 1.4 million pixels. The images are further enhanced by optical
filters and post image processing technology allowing detailed views of the mucosal archi‐
tecture. This in turn allows improved accuracy of diagnosis. We explore the roles of high
definition white light endoscopy, chromoendoscopy, confocal endomicroscopy and EUS in
the diagnosis and staging of esophageal neoplasia.
© 2013 Haidry and Lovat; licensee InTech. This is an open access article distributed under the terms of the
Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits
unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
2. White Light Endoscopy (WLE)
This process has several limitations. White light endoscopy is not sensitive enough to detect
neoplasia in pre-cancerous conditions in the upper GI tract. For example in Barrett’s esopha‐
gus, the standard approach is to take one biopsy in every quadrant of the Barrett’s segment
every 1-2 cm and send for histopathological review [1]. If biopsies are taken every 2 cm, the
average number per procedure is 12 and if taken every 1cm, this number will double. Even
with an efficient endoscopy setup, it takes around 30 seconds per biopsy so the procedure
takes up to 30 minutes to perform. It is also very time consuming for the pathologist, need‐
ing up to 30 minutes to evaluate a set of biopsies from a single endoscopy. Dysplasia and
early BE neoplasia result in subtle changes that may not often be visible with WLE examina‐
tion. In addition, random biopsies have significant sampling error since intestinal metapla‐
sia and dysplasia have a patchy distribution and only a small fraction of the BE segment is
sampled in this way. Even the most rigorous biopsy protocols including those using jumbo
biopsy forceps survey less than 1% of the esophageal mucosa and still miss up to one third
of cases with high-grade dysplasia (HGD) or early cancer [2-5].
3. Chromoendoscopy
The use of chromoendoscopy in the GI tract was first described in 1977 [6], and involves the
topical application of stains or pigments to improve visualization of the mucosa during en‐
doscopy. The basics of performing chromoendoscopy require only a small number of items:
staining agents, spray catheters, water rinses, and mucolytic agents. There are three main
types of stains that are used:
i. Absorptive stains (methylene blue, Lugol’s solution)
ii. Contrast stains (indigo carmine, acetic acid)
iii. Reactive stains such as congo red or phenol
There are two essential principles in chromoendoscopy: mucus removal and dye applica‐
tion. The former is achieved by using water, or occasionally some centers have advocated
the use of a mucolytic agent; N-Acetylcysteine [7-9]. This can be achieved by flushing the
agent through the working channel, using a spray catheter or even administering it as an
oral solution before the endoscopic procedure. Once the mucus is cleared, the dye can then
be applied.
3.1. Methylene Blue (MB) chromoendoscopy
MB, an absorptive dye, is probably the most investigated stain for evaluation of BE. MB is
applied topically at a concentration of 0.5-1.0% and is absorbed by goblet cells present in
metaplastic Barrett’s epithelium. Much of the early work on MB has been performed by
Canto’s group [10]. The first series published in 1996 assessed 14 patients with Barrett's
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esophagus and 12 control patients. Methylene blue stained specialized columnar epithelium
in 18 of the 26 patients, including those with intramucosal carcinoma (1), high-grade dyspla‐
sia (1), and indefinite/low-grade dysplasia (6). The overall sensitivity of methylene blue
staining for the biopsy finding of specialized intestinal metaplasia was 95%. The same group
then went on to a prospective, sequence randomized, trial of MDMB versus standard sur‐
veillance endoscopy with 2cm quadrantic biopsy [11]. 41 patients were studied with each
procedure performed by separate endoscopists within an interval of 3 to 4 weeks. The aver‐
age number of biopsies was significantly lower with MBDB than 2cm quadrantic biopsy but
the MB staining added a mean of 7 minutes (range 2 to 12 minutes) to the endoscopy proce‐
dure. Dysplasia or cancer was diagnosed in significantly more biopsy specimens (12%




Figure 1. Example of diffuse staining. Esophagus seen before and after staining with diffuse, uniform methylene blue
staining [14].
The problems with MB in BE is that dysplastic areas do not stain. Furthermore even areas
which do not harbor IM do not absorb the dye. This makes it difficult for the endoscopist to
decide on which areas to target the biopsies during the procedure. There are also some is‐
sues with the uniformity of the dye. It has been examined in both long and short segment BE
[12,13,15]. Two patterns of staining have been documented - diffuse and focal. Canto et al.
[15] found that most patients with long segment BE exhibited diffuse staining, whereas Wo
et al. [16] observed focal staining in their cohort of patients with long segment BE. Similar
results have been found when examining short segment BE by Sharma et al. [17] who found
that the majority of their patients with short segment BE stained diffusely. In contrast, in 30
patients with short segment BE assessed by Kiesslich’s group [18], only 80% demonstrated
staining in a focal pattern.
A recent meta-analysis assessing the diagnostic yield of MB in detecting intestinal and dys‐
plasia in BE looked at 9 published studies that included 450 patients. Despite controlling for
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differences in technique and quality of published data, the meta-analysis showed no signifi‐
cant benefit of MB chromoendoscopy compared with random biopsies in detecting SIM,
dysplasia or early esophageal cancer [19].
Unfortunately MB is inconvenient to use. It must be left in contact with the mucosa for 3 mi‐
nutes followed by vigorous washing to clear away excess dye. As a result the endoscopic
appearances are unpredictable, subjective and not reproducible
3.2. Acetic acid chromoendosocpy
Acetic acid 2.5% (AA) when sprayed onto Barrett’s mucosa causes a reversible acetylation of
nuclear proteins to occur. This leads to an acetowhitening reaction, with increased opacity of
the mucosal surface. It also causes vascular congestion and improves surface pattern evalua‐
tion. There is a growing body of evidence that magnification chromoendoscopy with acetic
acid improves the diagnosis of specialized intestinal metaplasia. The technique is advanta‐
geous as it is both safe and inexpensive. When topically applied to multilayered squamous
epithelium the acetic acid is progressively neutralized by mucus covering the epithelium
and the underlying stroma and the vascular network are protected [20]. In single layered
columnar lined esophagus the acetic acid reversibly alters the barrier function of the epithe‐
lium and reaches the stroma and vascular network. This leads to swelling of the mucosal
surface and enhancement of the surface architecture. There is also enhancement of vascular
pattern due to congestion of the capillaries. Transient changes to the structure of cellular
proteins may also occur.
Figure 2. Acetic acid used to visualise Barrett’s oesophagus, ridge pattern signifying Intestinal metaplasia
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All of the studies using acetic acid have combined magnification endoscopy to study the pit
pattern of the mucosa. Classification is based on Guelrud’s description of four typical pit
patterns; gastric patterns (pattern I = pits with a regular and orderly arranged circular dots;
pattern II = reticular pits that are circular or oval and are regular in shape and arrangement);
SIM patterns (pattern III = fine villiform appearance with regular shape and arrangement;
pattern IV = thick villous convoluted shape with a cerebriform appearance with regular
shape and arrangement).
In the first prospective cohort study of 49 patients, sensitivity for specialized intestinal meta‐
plasia = 96.5%, specificity = 88.7% and overall accuracy was 92.2% [21]. Using modified crite‐
ria, a second study of 67 patients demonstrated sensitivity 88.5%, specificity 90.2% and
diagnostic accuracy of 90% [22]. Reaud et al. studied 28 patients with a type III or IV pattern
with sensitivity for SIM of 95.5%, specificity 42.9 % and diagnostic accuracy of 75% [23].
A further randomised crossover study using acetic acid for the detection of Barrett’s metapla‐
sia in 32 patients was performed by Hoffman et al. [24]. Patients were randomized to either
standard video endoscopy with quadrantic biopsies or to magnifying endoscopy with acetic
acid. All patients were re-examined after 14 days post initial endoscopy with the correspond‐
ing procedure. The investigators found that magnifying endoscopy enabled the prediction of
Barrett’s epithelium with a sensitivity of 100% and specificity of 66% and accuracy of 83.8%.
The biopsies obtained following exposure to acetic acid yielded a significantly higher percent‐
age of tissues containing Barrett’s metaplasia (78%) compared to random biopsies (57%). Again
this study had no dysplasia cases and the authors recognized this as a limitation of the study.
In a very recent landmark study by Longcroft-Wheaton et al. [25] from Portsmouth in the
United Kingdom, the efficacy of acetic acid has been investigated in detecting Barrett’s dys‐
plasia. Data were collected from 190 patients with Barrett's esophagus examined over a 3
year period at a tertiary referral center from procedures performed by a single experienced
endoscopist. Patients were first examined with white light gastroscopy and visible abnor‐
malities were identified. Acetic acid (2.5%) dye spray was used to identify potentially neo‐
plastic areas and biopsy samples were collected from these, followed by quadrantic biopsies
at 2 cm intervals of the remaining Barrett's mucosa. The chromoendoscopic diagnosis was
compared with the ultimate histological diagnosis to evaluate the sensitivity of acetic acid
chromoendoscopy. Acetic acid chromoendoscopy had a sensitivity of 95.5% and specificity
of 80% for the detection of neoplasia. There was a correlation between lesions predicted to
be neoplasias by acetic acid and those diagnosed by histological analysis (r = 0.98). There
was a significant improvement in the detection of neoplasia using acetic acid compared with
white light endoscopy (P = 0.001).
3.3. Indigo carmine chromoendoscopy
Whilst Indigo carmine has been used in many studies looking at colonic neoplasia, it has not
been studied to such a degree in the esophagus. As in the colon, it is not absorbed by esopha‐
geal and Barrett’s mucosa, but accumulates in the pits and valleys between cells, highlighting
the architecture. It is a contrast agent which can highlight mucosal irregularities and has been
very helpful in the colon. However, results have been less encouraging in the esophagus.
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Sharma et al. showed that using indigo carmine and high resolution endoscopy 3 distinct
patterns can be recognized at endoscopy: ridged and/or villous, circular, and irregular
and/or distorted [26]. Barrett’s epithelium was most commonly identified in the ridged-vil‐
lous pattern, whereas high-grade dysplasia was found entirely in the irregular/distorted pat‐
tern. An irregular/distorted pattern either throughout the entire segment of Barrett’s
esophagus or in combination with a ridge/villous or circular pattern had a sensitivity or
83%, a specificity of 88%, a positive predictive value of 45%, and a negative predictive value
of 98% for high-grade dysplasia.
Figure 3. High−resolution white−light imaging (left) and indigo carmine chromoendoscopy (right) of a small mucosal
lesion (type IIb) at the 6−o’clock position (arrows), detected in a patient with Barrett’s esophagus. This area was re‐
garded as suspicious after spraying of indigo carmine. High grade dysplasia was found in the corresponding biopsy
specimens [27].
4. HD WLE & optical enhancements
Video endoscopy relies on a charge coupled device (CCD) chip to enhance image resolution
and magnification. Standard definition (SD) WLE is rapidly being replaced by the introduc‐
tion of high definition endoscopes. Video endoscopes use white light from a xenon or halo‐
gen source for illumination. The reflected light is captured by a CCD chip at the tip of the
instrument in order to reconstruct the images. Conventional SD endoscopes are equipped
with CCD chips that produce an image signal of 100,000 to 400,000 pixels which is displayed
in SD format. The chips currently in use in HD endoscopes produce resolutions that range
from 850,000 to 1.3 million pixels. In order to generate a true HD image, each component of
the system (e.g. the endoscope CCD chip, the processor, the monitor, and transmission ca‐
bles) must be HD compatible.
4.1. Enhanced imaging systems – Olympus Narrow Band imaging (NBI)
Conventional WLE uses the entire spectrum of visible light (400-700mm) to examine tissue.
Narrow band imaging (NBI) developed by Olympus Medical Systems (Olympus, Japan) is a
new advance in endoscopy that uses optic filters to isolate two specific bands of light: 415
nm blue and 540 nm green. By isolating these two bands of light and taking into account
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their absorptive and reflective properties on the mucosal surface, an image that enhances
visualization of superficial mucosal and vascular structures is created. The quality of the
surface pit pattern morphology is also clearly enhanced by this technology. It enables the en‐
doscopist to switch between conventional white light and NBI views easily and quickly dur‐
ing the procedure, thus making the procedure itself less messy and cumbersome compared
to chromoendoscopy. By depressing a lever on the endoscope, the focal distance of the lens
at the tip of the endoscope can be adjusted electronically thus enabling the endoscopist to
achieve a maximal magnification of 115X in real time.
Figure 4. NBI uses two discrete bands of light: One blue at 415nm and one green at 540nm. Narrow band blue light
displays superficial capillary networks, while green light which penetrates more deeply into tissue displays subepithe‐
lial vessels and when combined offer an extremely high contrast image of the tissue surface.
Figure 5. NBI image on the monitor: Capilaries on the surface are displayed in brown and veins in the sub surface are
displayed in cyan.
Novel Imaging Techniques in Gastrointestinal Endoscopy in the Upper Gastrointestinal Tract
http://dx.doi.org/10.5772/53807
143
Figure 6. Light filtering in the narrow-band imaging system. The white light is split into two narrow bands: a blue
narrow band of 415 nm and a green narrow band of 540 nm.
Although many studies have shown the benefit of NBI over conventional WLE in detect‐
ing HGD and early esophageal cancer, others have questioned whether NBI achieves any
incremental improvement beyond that of HRE-WLE. Wolfsen et  al.  investigated whether
NBI targeted biopsies could detect advanced dysplasia using fewer biopsy samples com‐
pared with conventional endoscopy using the four-quadrant biopsy method with a pro‐
spective,  blinded,  controlled  tandem  study  [28].  The  study  revealed  that  NBI  detected
dysplasia  in  57%  of  patients  compared  with  43%  in  the  conventional  endoscopy  with
four-quadrant biopsy group, with higher grades of dysplasia detected in the NBI group
(P  <  0.001).  In  addition,  more  biopsies  were  taken  in  the  four-quadrant  biopsy  group
compared with narrow-band targeted biopsies (mean 8.5 versus 4.7;  P < 0.001).  A study
by Kara et al.  investigated chromoendoscopy versus NBI, both in combination with high
resolution  endoscopy,  in  a  prospective,  randomized  crossover  study  with  14  patients
[29].  The sensitivity of chromoendoscopy and NBI was 93% and 86%, respectively, com‐
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pared with 79% for four-quadrant biopsies with conventional endoscopy in the diagnosis
of high-grade dysplasia or early cancer (EC) in patients with BE. Although chromoendo‐
scopy and NBI identified additional lesions (chromoendoscopy two additional lesions in
two patients; NBI four additional lesions in three patients), they did not increase per pa‐
tient sensitivity for identifying HGD/EC.
Interestingly, in an inter-observer agreement study by Curvers et al.  there was moderate
inter-observer  agreement  for  classification  of  mucosal  morphology  by  NBI  (0.40–0.56)
[30].  Although  there  was  improvement  in  image  quality  with  NBI  compared  to  HRE,
NBI provided no significant  improvement in inter-observer variability  and yield for  de‐
tecting neoplasia.  The yield of HRE-WLE for neoplasia was 81%, 72% for NBI, and 83%
for  the  HRE-WLE with  NBI.  The  addition  of  enhancement  techniques  did  not  improve
the yield of neoplasia in this series.
More recently Curvers et al. have performed a review of studies that analyzed NBI images
for accuracy in differentiating HGD/cancer from low-grade dysplasia (LGD) or non-neoplas‐
tic Barrett’s esophagus [31]. In a meta-analysis that included 149 areas with HGD/cancer and
607 areas with LGD or non-dysplastic Barrett’s esophagus, NBI had a sensitivity for HGD/
cancer of 97% (95% CI 89– 99%) and a specificity of 94% (60–99%), and an accuracy of 96%
(72–99%). Consequently, the use of ‘targeted’ biopsy techniques using image enhancement
techniques has potential time and cost savings. They recognize however that these findings
may not be generalizable as these studies were performed in high-risk populations.
4.2. Comparing high definition WLE to enhanced imaging systems (NBI)
The majority of studies looking at NBI compare its efficacy in relation to other endoscopic
modalities such as chromoendoscopy or autofluorescence as well as HD-WLE. There are
limited data directly comparing the efficacy of NBI versus HD-WLE in the diagnosis of dys‐
plasia/early cancer in patients with Barrett’s esophagus. A very recent randomized control
trial from 2012 by Sharma et al [32] compared the use of HD WLE and NBI for detection of
IM or dysplasia in patents with BE. Patients referred for BE screening or surveillance at
three tertiary referral centers were prospectively enrolled and randomized to HD-WLE or
NBI followed by other procedures in 3-8 weeks. During HD-WLE, four quadrant biopsies
every 2 cm, together with targeted biopsies of visible lesions (Seattle protocol), were ob‐
tained. During NBI examination, mucosal and vascular patterns were noted and targeted bi‐
opsies were obtained. 123 patients with BE (mean age 61; 93% male; 97% Caucasian) with
mean circumferential and maximal extents of 1.8 and 3.6 cm, respectively, were enrolled.
Both HD-WLE and NBI detected 104/113 (92%) patients with IM, but NBI required fewer bi‐
opsies per patient (3.6 vs 7.6, P < 0.0001). NBI detected a higher proportion of areas with
dysplasia (30% vs 21%, P = 0.01). During examination with NBI, all areas of HGD and cancer
had an irregular mucosal or vascular pattern. This important study demonstrates that NBI
targeted biopsies can have the same IM detection rate as an HD-WLE examination with the
Seattle protocol while requiring fewer biopsies. In addition, NBI targeted biopsies can detect
more areas with dysplasia. Regular appearing NBI surface patterns did not harbor high-
grade dysplasia/cancer, suggesting that biopsies could be avoided in these areas.
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Figure 7. High magnification white light endoscopy-round pits in keeping with columnar mucosa without intestinal
metaplasia with corresponding area on right image seen with narrow band imaging (NBI) and magnification
4.3. Enhanced imaging systems – Pentax medical i-scan
A new endoscopic image enhancement technology, i-scan, has been developed by PENTAX
(HOYA Corporation), Japan. i-Scan uses the EPKi processor technology which enables reso‐
lution above HDTV standard, with distinct digital filters for special post processing online
imaging, which can provide detailed analysis. i−Scan is a novel endoscopic post processing
light filter technology using sophisticated software algorithms with real time image map‐
ping technology embedded in the EPKi processor. The computer controlled digital process‐
ing provides resolution of about 1.25 mega pixels per image. Different elements of the
mucosa are enhanced by pressing a button on the hand piece of the high definition endo‐
scope. i−Scan can be used for surface analysis to recognize lesions using three modes of im‐
age enhancement. These are:
i. Surface enhancement (SE)/ i-scan 1 – enhancement of the structure through recogni‐
tion of the edges
ii. Contrast enhancement (CE)/ i-scan 2 – enhancement of depressed areas and differen‐
ces in structure through colors presentation of low density areas
iii. Surface and Tone enhancement (TE)/ i-scan 3– enhancement tailored to individual or‐
gans through modification of the combination of RGB components for each pixel
i-scan images are as bright as conventional WLE images and therefore i-scan can observe
larger  areas in a  distant  view than NBI.  i-scan does not  need magnifying endoscopy to
observe the demarcation between normal and abnormal tissue. i–scan can be switched on
and  effected  quite  simply  and  instantaneously  by  pushing  a  button,  therefore  it  is  an
easy method for  screening or  detailed inspection,  and may reduce both time and costs.
The sensitivity and specificity of i-scan in detecting dysplasia in Barrett’s  patients is  yet
to be investigated.
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There is as of yet no formal i-scan classification system for BE mucosal patterns. However
using those devised for other modalities such as NBI, endoscopists are able to direct and tar‐
get therapy to subtle anomalies based on these validated classification systems. There is
however a growing body of work showing the increased accuracy of i-scan in the colon in





i-scan 3  i-scan 2 
i-scan 1 
Figure 8. Pentax Images of an area of BE mucosa with IM using the various enhancement settings
4.4. Flexible spectral imaging color enhancement (FICE)
Unlike NBI, which utilizes a physical filter, FICE (Fujinon, Japan) is a post processor tech‐
nology which captures spectral reflectance by a color CCD video endoscope. This is sent to a
spectral estimation matrix processing circuit contained in the video processor. The reflec‐
tance spectra of corresponding pixels that make up the conventional image are mathemati‐
cally estimated. From these spectra, it is feasible to reconstruct a virtual image of a single
wavelength. Three such single-wavelength images can be selected and assigned to the red,
green, and blue monitor inputs, respectively, to display a composite color-enhanced multi
band image in real time. In practice this can be used like narrow band imaging to remove
data from the red part of the waveband and narrow the green and blue spectra
A prospective cohort study of 72 patients demonstrated that the identification of Pallisade
vessels using FICE provided a clear demarcation between Barrett’s mucosa and the gastric
mucosa which was superior to standard white light endoscopy [34]. This study did not at‐
tempt to diagnose dysplasia and used transnasal Fujinon endoscopes. These are very small
with a more limited field of view and no optical magnification.
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In a small prospective cohort study of 57 patients which compared FICE with random biop‐
sy in patients with suspected HGD or early cancer arising in BE, a sensitivity of 92% and
specificity of 97% for FICE was achieved [35]. There was HGD or early cancer in 24/57 pa‐
tients. However the investigators used acetic acid in addition to FICE.
5. Mucosal classification systems for dysplasia in BE
There are now several recognized mucosal classification systems that have been described in
the literature. They have formed the basis for further extensive work attempting to validate
numerous optical enhancement modalities for neoplasia in BE. 2 of the very first systems
were defined by Guelred et al. and Endo et al. in 2001 and 2002.
Guelrud et al  [36] in 2001 described a technique they named enhanced-magnification en‐
doscopy,  which combines  magnification endoscopy with instillation of  acetic  acid.  They
classified  Barrett’s  mucosa  into  4  patterns:  I,  round  pits;  II,  reticular  (circular  or  oval
pits); III, villous (fine villiform appearance without visible pits); and IV, ridged (thick vil‐
li  with  convoluted  cerebriform  appearance  without  visible  pits).  This  initial  study  by
Guelrud et al. included 49 patients undergoing endoscopic surveillance for short-segment
Barrett’s  esophagus.  At  the  time  the  study  was  conducted,  a  magnification  endoscope
with standard resolution and a  magnification power of  35x was used.  A spray catheter
was used to apply approximately 10 to  15 mL of  1.5% acetic  acid onto the distal  oeso‐
phagus.  This  technique added an estimated 5  to  8  minutes  to  the  length of  a  standard
endoscopic  examination.  The  4  different  mucosal  surface  patterns  were  observed,  and
one biopsy specimen was taken from each representative pattern.  All  patients with Bar‐
rett’s esophagus had a villiform mucosal pattern that correlated with the finding of intes‐
tinal  metaplasia  on  histopathologic  evaluation  of  the  biopsy  specimens.  The  yield  of
biopsy specimens in the detection of intestinal metaplasia was correlated with the endo‐
scopic pattern. Biopsy specimens from Pattern I mucosa revealed fundic epithelium, and
this pattern served as a control for the analysis. Biopsy specimens from Pattern II muco‐
sa revealed cardia mucosa in 90% of cases; intestinal metaplasia was found in two of 18
samples.  Analysis  showed  that  Pattern  III  and  Pattern  IV  mucosa  contained  intestinal
metaplasia  in  87% and 100% respectively  of  biopsy  specimens.  The  overall  accuracy  of
enhanced  magnification  endoscopy  for  the  detection  of  intestinal  metaplasia  was  92%;
the positive predictive value of Patterns III and IV was 87.5%.
In  2002  Endo  et  al.  [37]  examined  67  regions  in  Barrett’s  mucosa  and  described  5  pat‐
terns.  These  patterns  were  classified into  5  categories.  The dot  type (pit-1)  is  character‐
ized by small  round pits  of  relatively  uniform size  and shape.  The straight  type (pit-2)
consists of long straight lines. The long oval and curved type (pit-3) exhibits long extend‐
ed pits, larger than those of the dot type (pit-1). The tubular type (pit-4) has a complicat‐
ed  and  twisted  pattern  that  is  similar  to  a  branch  or  gyrus-like  structure.  The  fifth
pattern  (pit-5),  villous  type,  has  flat,  finger-like  projections.  Methylene  blue  is  applied
topically at  a  concentration of  0.5-1.0% and is  absorbed by goblet  cells  present in meta‐
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plastic Barrett’s epithelium. Methylene blue stained 0% of the mucosa identified as types
1 and 2. However, intestinal metaplasia was found in 6% of biopsy specimens from mu‐
cosa that exhibited the type 1 pattern.  The rate of  positive methylene blue staining was
23% for type 3, and 40% of biopsy specimens from this type revealed intestinal metapla‐
sia.  Intestinal  metaplasia was found in 100% of biopsy specimens from mucosa that  ex‐
hibited  either  a  type  4  or  type  5  pattern.  However,  type  4  and  type  5  mucosa  were
stained by methylene blue in only 60% and 50% of cases, respectively.
Figure 9. The First Guelrud classification (x35, 1.5% alcohol acetic acid); Pattern I: round pits with a regular and order‐
ly arranged circular dots. Pattern II: reticular pits that are circular or oval and are regular in shape and arrangement.
Pattern III: fine villiform appearance with regular shape and arrangement. Pattern IV: thick villous convoluted shape
with a cerebriform appearance with regular shape and arrangement. Guelrud et al [36]
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Figure 10. Endo Classification of pit pattern of Barrett’s epithelium by magnifying endoscopy. Endoscopic views at
right were obtained without methylene blue staining and those at left after application of methylene blue. Note that
mucosa with pit-1, pit-2, and pit-3 patterns was not stained by the dye, whereas positive staining is evident within
mucosa with pit-4 and pit-5 patterns Endo et al. [37]
Kara et al. in 2006 from Amsterdam [38] suggested a further classification system. They used
NBI with magnifying endoscopy to image and then biopsy randomly selected areas in 63 pa‐
tients with BE. Following this there was a formal review process of the images and biopsies.
The relationship between mucosal morphology and presence of IM and HGD were evaluat‐
ed. Areas of intestinal metaplasia were characterized by either villous/gyrus-forming pat‐
terns (80%), which were mostly regular and had regular vascular patterns, or a flat mucosa
with regular normal-appearing long branching vessels (20%). HGD was characterized by 3
abnormalities: irregular/disrupted mucosal patterns, irregular vascular patterns, and abnor‐
mal blood vessels. All areas with HGIN had at least 1 abnormality, and 85% had 2 or more
abnormalities. The frequency of abnormalities showed a significant rise with increasing
grades of dysplasia. The magnified NBI images had a sensitivity of 94%, a specificity of 76%,
a positive predictive value of 64%, and a negative predictive value of 98% for HGIN.
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Figure 11. Magnified high-resolution white light (left) and NBI (right) endoscopic photographs of areas with nondys‐
plastic BE (no staining, orig. mag.115). The upper 3 examples have regular villous/gyrus-forming mucosal patterns
with regular vascular patterns; the villi are of various sizes and shapes but regular in all areas with blood vessels situat‐
ed between the mucosal ridges. The lower image has a flat-type mucosa without pits or villi; the vasculature shows
regular, normal-appearing long branching vessels. Kara et al. [38]
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Figure 12. Magnified high-resolution white light (left) and corresponding NBI (right) endoscopic photographs of
areas with HGIN in BE (no staining, orig. mag. _115). These examples show irregular/disrupted mucosal patterns, with
irregular vascular patterns with remnants of villous/gyrus-forming mucosal patterns. Kara et al. [38]
Singh et al. [39] from Nottingham in the United Kingdom have looked at an alternative sim‐
plified classification. In a prospective cohort study of 109 patients with Barrett’s esophagus,
mucosal patterns visualized with NBI were classified into four easily distinguishable types:
A, round pits with regular microvasculature; B, villous/ridge pits with regular microvascu‐
lature; C, absent pits with regular microvasculature; D, distorted pits with irregular micro‐
vasculature. The NBI grading was compared with the final histopathological diagnosis. In
903 out of 1021 distinct areas (87.9%) the NBI grading corresponded to the histological diag‐
nosis. The PPV and NPV for type A pattern (columnar mucosa without intestinal metapla‐
sia) were 100% and 97% respectively; for types B and C (intestinal metaplasia) they were
88% and 91% respectively, and for type D (high grade dysplasia) 81% and 99% respectively.
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With respect to inter- and intra-observer agreement, the mean k values in assessing the vari‐
ous patterns were 0.71 and 0.87 in the non-expert group; 0.78 and 0.91 in the expert group.
Figure 13. (A) Type A: round pits with regular microvasculature. (B) Type B: villous/ridge pits with regular microvascu‐
lature. (C) Type C: absent pits with regular microvasculature. (D) Type D: distorted pits with irregular microvasculature.
Singh et al. [39]
A final endoscopic classification system for BE was described by investigators in Kansas
again using narrow band imaging [40]. NBI images were graded according to mucosal pat‐
tern (ridge/villous, circular and irregular/distorted) and vascular pattern (normal and abnor‐
mal), and correlated with histology. Of 51 patients, 28 had IM without dysplasia, 8 had low-
grade dysplasia (LGD), 7 had high-grade dysplasia (HGD), and 8 had cardiac-type mucosa.
The sensitivity, specificity, and positive predictive value of ridge/villous pattern for diagno‐
sis of IM without HGD were 93.5%, 86.7%, and 94.7%, respectively. The sensitivity, specifici‐
ty, and positive predictive value of irregular/distorted pattern for HGD were 100%, 98.7%,
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and 95.3%, respectively. If biopsies were limited to areas with irregular/distorted pattern, no
patient with HGD would have been missed. However, NBI was unable to distinguish areas
of IM from those with LGD.
6. Interobserver agreement of classification criteria
A potential drawback with all these classification systems has been the lack of intra-observer
agreement between endoscopists when using the classification systems described above.
In order to compare the 3 above classification systems from Amsterdam, Nottingham and
Kansas a recent comparative study was performed by Silva et al. [41]. They examined all 3
classification systems in 84 high quality video recordings collected on cases of BE using HD
WLE and NBI. All assessors were blinded to the matched histology form these areas. The
global accuracy was 46% and 47% using the Nottingham and Kansa classifications respec‐
tively and 51% with the Amsterdam Classification. Accuracy for detecting dysplastic lesions
was 75% irrespective of classification system used. The inter-observer agreement ranged
from fair (Nottingham ĸ=0.34) to moderate (Amsterdam and Kansas, ĸ=0.47 and ĸ=0.44, re‐
spectively). The authors concluded that all three systems revealed substantial limitations
when assessed externally and that as a result, NBI could not replace random biopsies for
histopathological analysis.
7. Confocal laser endomicrospcopy (CLE)
CLE is a new technology that enables the endoscopist to perform a real time histological
assessment of the upper gastrointestinal tract and in particular the esophagus. The most
widely used CLE system is  the ‘endoscope with embedded CLE technology’ (eCLE)
made  by  Pentax,  Tokyo,  Japan  and  Optiscan,  Melbourne,  Australia.  The  eCLE  enables
visualization of both the epithelium and the subepithelial vascular structures with imag‐
ing  at  variable  depths  up  to  250mm  and  a  magnification  power  of  up  to  1000µm.  A
probe-based  endomicroscopy  system  has  been  created  by  Mauna  Kea  Technologies  in
which  the  laser-scanning  unit  remains  outside  the  patient,  and  the  endomicroscopy
probe is passed through the working channel of a standard endoscope. This probe-based
CLE (pCLE) provides video sequence imaging at a rate of 12 images per second and al‐
lows for  the  compilation of  images  from a  video sequence  to  create  a  composite  video
mosaic.  The  depth  ranges  from 50  to  150mm and is  fixed based on  the  type  of  probe.
These  CLE  systems  use  a  wavelength  of  48nm  for  excitation.  CLE  requires  the  use  of
contrast  agent,  most  commonly intravenous fluorescein sodium, which is  safe  for  imag‐
ing the gastrointestinal tract [42].
CLE classification systems for Barrett’s esophagus with and without dysplasia have been de‐
scribed for standard endomicroscopy and probe-based endomicroscopy [43,44]. Signs of
non-dysplastic Barrett’s epithelium include a regular epithelial lining pattern, regular vascu‐
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lar pattern, presence of goblet cells, and preservation of the villous pattern of glands. Signs
of dysplasia in Barrett’s esophagus include irregular epithelial lining, fusion of glands, focal
accumulation of dark cells with bright lamina propria, irregular vascular pattern, and dis‐
ruption of the glandular pattern.
Kiesslich et al. [43] demonstrated that eCLE could diagnose Barrett’s associated dysplasia
during endoscopy with a sensitivity of 92.9% and a specificity of 98.4%. Dunbar et al. [45]
conducted a prospective, double-blind, randomized crossover study comparing four-quad‐
rant random biopsies with eCLE-targeted biopsy in 39 patients. They demonstrated that
eCLE improved the diagnostic yield for detecting neoplasia in Barrett’s esophagus. The
yield of eCLE was 33.7% versus 17.2% with random biopsies (P 1⁄4 0.01). Furthermore, some
patients undergoing eCLE would not have needed any random biopsies in order to diag‐
nose neoplasia.
In 2011 Gaddam et al. [46] revised and validated a set of criteria for pCLE for dysplasia in BE
using video recordings. Of multiple pCLE criteria tested in the first phase of their study, on‐
ly those with ≥70% sensitivity or specificity were included in the final set. These were epi‐
thelial surface: saw-toothed; cells: enlarged; cells: pleomorphic; glands: not equidistant;
glands: unequal in size and shape; goblet cells: not easily identified. Using these criteria
overall accuracy in diagnosing dysplasia was 81.5% (95% CI: 77.5–81), with no difference be‐
tween experts vs. non-experts. Accuracy of prediction was significantly higher when endo‐
scopists were “confident” about their diagnosis (98% (95–99) vs. 62% (54–70), P<0.001).
Accuracy of dysplasia prediction for the first 30 videos was not different from the last 45 (93
vs. 81%, P=0.51). Overall agreement of the criteria was substantial, ĸ = 0.61 (0.53–0.69), with
no difference between experts and non-experts.
In a very recent international prospective, multicenter, randomized controlled trial, Shar‐
ma et al.  [47] investigated whether pCLE could allow for real time detection of neoplas‐
tic  Barrett’s  esophagus.  All  patients  with  BE were  examined by HD-WLE,  narrow-band
imaging (NBI),  and pCLE,  and the findings were recorded before matched biopsy sam‐
ples were obtained. The order of HD-WLE and NBI was randomized and performed by
2 independent,  blinded endoscopists.  All  suspicious  lesions  on HD-WLE or  NBI  and 4-
quadrant  random  locations  were  documented.  These  locations  were  then  examined  by
pCLE, and a presumptive diagnosis of  benign or neoplastic (HGD/EC) tissue was made
in real  time after which biopsies were taken from all  locations and were reviewed by a
central pathologist,  blinded to endoscopic and pCLE data. The sensitivity and specificity
for  HD-WLE were  34.2% and 92.7%,  respectively,  compared with  68.3% and 87.8%,  re‐
spectively,  for HD-WLE or pCLE (P = 0.002 and P < 0.001,  respectively).  The sensitivity
and specificity for HD-WLE or NBI were 45.0% and 88.2%, respectively,  compared with
75.8% and 84.2%, respectively, for HD-WLE, NBI, or pCLE (P = 0.01 and P = 0.02, respec‐
tively).  However  with  the  use  of  pCLE in  conjunction with  HD-WLE and NBI  enabled
the identification of  2  and 1  additional  HGD/EC patients  compared with  HD-WLE and
HD-WLE  or  NBI,  respectively,  resulting  in  detection  of  all  HGD/EC  patients,  although
not statistically significant. This may allow better informed decisions to be made for the
management and subsequent treatment of BE patients.
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Figure 14. Images of normal, dysplastic and cancer using probe based confocal endomicrosocpy. The presence of
goblet cells denoted intestinal metaplasia. (The images are courtesy of the DONT BIOPCE trial)
7.1. OCT – Optical Coherence Tomography
Optical Coherence Tomography (OCT) is an imaging modality that may have the ability
to  improve  the  current  paradigm  for  endoscopic  screening  and  surveillance  that  exists
for  patients  with  BE.  OCT can be  thought  of  as  an  analogous  technique to  ultrasound,
however,  instead of  producing an image from the scattering of  sound waves,  it  utilizes
optical  scattering based on differences  in  tissue composition to  form a two-dimensional
image [48].  The benefit  of OCT over ultrasound is that it  is capable of generating cross-
sectional images of tissues with an axial-resolution of up to 10µm, which is comparable
to low-power microscopy.
Original OCT systems or time-domain OCT were limited to discrete locations or ‘point’ sam‐
pling due to slow acquisition rates. However, with the development of second-generation
OCT, termed Optical Frequency Domain Imaging (OFDI), it is now possible to perform
high-speed acquisition of large luminal surfaces in three-dimensions [49]. Due to its high-
resolution and high-acquisition rates, utilizing this technique for screening and surveillance
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of Barrett’s esophagus may provide a means to evaluate pathologic states in long-segments
of the esophageal lumen in real-time.
7.2. OCT in Barrett’s esophagus
The  first  clinical  application  using  in  vivo  endoscopic  OCT  for  imaging  of  the  human
esophagus and stomach was performed by Bouma et al.  in 2000 [50]. In this preliminary
study,  the  ability  of  OCT  to  image  normal  esophageal  mucosa  and  stomach,  Barrett’s
esophagus, and adenocarcinoma was investigated. The authors concluded that they were
able to differentiate the normal layered structure of the esophagus using OCT, including
epithelium,  lamina  propria,  muscularis  mucosa,  and  submucosa.  In  addition,  OCT  was
capable  of  differentiating  between  normal  esophageal  mucosa  and  Barrett’s  esophagus
based on the lack of the layered structure found in Barrett’s esophagus as well as a dis‐
organized glandular morphology. Finally, esophageal adenocarcinoma was clearly differ‐
entiable  by  the  presence  of  marked  architectural  disorganization.  Several  studies
immediately  followed  this  landmark  study  using  in  vivo  OCT  for  the  GI  tract  [51-54].
Similarly,  they  utilized  a  non-contact  probe,  approximately  2.5mm  in  diameter,  intro‐
duced through the auxiliary channel of a standard endoscope. These studies all were sig‐
nificant  in the contribution of  development of  OCT for GI imaging and played a major
role  in  the  potential  clinical  utility  of  OCT,  however,  they were  limited to  ‘point’  sam‐
pling and did not address diagnostic information relevant to dysplasia.
Subsequently, diagnostic criteria were developed for endoscopic OCT to diagnose special‐
ized intestinal metaplasia (SIM), high-grade dysplasia (HGD), and intramucosal carcinoma
(IMC). In prospective studies performed by Poneros et al. and Evans et al., sensitivities from
81%-97% and specificities from 57%-92% for diagnosing SIM were reported [55,56]. Addi‐
tionally, sensitivities and specificities for detecting HGD and IMC were reported in the
ranges of 54%-83% and 72%-75%, respectively [55,57]. Unfortunately, similar to previous in‐
vestigations, the studies were limited to ‘point’ sampling where a probe was placed at dis‐
crete locations and cross-sectional images were obtained. Although these studies made great
strides in the diagnostic potential of OCT, the true clinical utility for Barrett’s esophagus
was not realized due to the potential for sampling errors analogous to biopsy.
More recently, technological advancements and the development of a second-generation
OCT system, OFDI, has provided the ability to image long-segments of tissue with high-res‐
olution and contrast identical to those obtained in OCT but at a rate approximately 100-
times faster [58,59]. The first comprehensive imaging of the esophagus in human patients
using OFDI was performed by Suter et al. In this study, a balloon-centering optical catheter
was used to acquire long-segment (6cm) images of the esophagus during an endoscopic pro‐
cedure (<2 minutes) [60]. During system and catheter development, a total of 32 patients
were imaged prior to the design being unchanged. Once the final design had been establish‐
ed, a total of 10 patients out of 12 were successfully imaged using the comprehensive micro‐
scopy technique of OFDI, while 2 patients were not imaged due to imaging system
malfunction. No adverse events or patient-related complications were reported in the study.
Although the study presented promising case findings related to OCT diagnosis of normal
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esophagus and cardia, ulcerated squamous mucosa, specialized intestinal metaplasia, and
dysplasia, it was limited to image criteria established based on a non-contact OCT probe.
Additional studies are needed to develop diagnostic criteria, intra-observer and inter-ob‐
server variability in diagnosis of OFDI imaging, and an OFDI-histopathologic correlative
study using OFDI technology.
Figure 15. Optical Coherence Tomography images showing normal cardia and a cross sectional image through the
squamous oesophagus. (Courtesy of Ninepoint Medical)
7.3. Autofluorescence
When tissues are exposed to a short wave length light, endogenous biological substances
(i.e., fluorophores) are excited, leading to emission of fluorescent light of a longer wave‐
length. This phenomenon is known as autofluorescence. Autofluorescence imaging (AFI) is
a technique that can potentially differentiate tissue types based on their differences in fluo‐
rescence emission. Normal and neoplastic tissue have different autofluorescence spectra
which may enable their distinction. This is due to the various different compositions of the
endogenous fluorophores which includes collagen, NADH, aromatic amino acids and por‐
phyrins in these tissues. This phenomenon was first utilized in Barrett’s esophagus using
spectroscopic point measurements. In brief, low collagen fluorescence and high NAD(P)H
fluorescence characterize lesions with high grade dysplasia as opposed to non-dysplastic ep‐
ithelia. Hence, with progression towards neoplasia one would typically observe a reduction
in the intensity of green fluorescence, and a relative increase in red fluorescence.
In a 2006 60 patient study using a standard endoscope with an added AFI component, Kara
was able to detect HGD in 22 patients, 14 of which were detected with AFI and WLE, and
six of which were detected using AFI alone; thereby increasing the detection rate from 23%
to 33% using AFI [61]. Only one of the patients was diagnosed using the standard four-
quadrant biopsies alone. Results suggest that AFI may aid in the detection of additional
HGD sites; however, it may not exclude the need for the standard four-quadrant biopsies.
Sensitivity and specificity based on the 116 samples used for this study were 91% and 43%,
respectively. Although no patient was diagnosed without AFI and four-quadrant biopsies,
they cite a high rate of false positives using AFI alone, due in part to the loss of autofluores‐
cence associated with acute inflammation.
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8. VCE – Video Capsule Endoscopy
Wireless video capsule endoscopy (VCE) was approved by the Food and Drug Adminis‐
tration in 2001 as  an adjunctive aid for  the detection of  small  bowel  disorders.  Because
patients  ingest  the  capsule  in  the  standing  position  and the  small  bowel  VCE captures
two frames per second, the traditional VCE often does not capture images of the esopha‐
go-gastric junction (EGJ).
Developed in 2004, the Esophageal capsule, or PillCam ESO (Given Imaging, Ltd., Duluth,
GA, USA), captures 14 frames per second whereas the patient ingests the capsule in a supine
position and then gradually resumes the sitting position during a 5-minute period. Usage of
the first generation PillCam ESO demonstrated excellent sensitivity and specificity for the
detection of erosive esophagitis and BE in a preliminary study of 106 patients (93 with
GERD, 13 with BE). Sixty-six of 106 patients had positive esophageal findings, VCE identi‐
fied oesophageal abnormalities in 61 (sensitivity, 92%; specificity, 95%). The per-protocol
sensitivity, specificity, PPV, and NPV of VCE for Barrett oesophagus were 97%, 99%, 97%,
and 99%, respectively, and for esophagitis 89%, 99%, 97%, and 94%, respectively. VCE was
preferred over conventional upper GI endoscopy by all patients. There were no adverse
events related to VCE. The investigators concluded that VCE is a convenient and sensitive
method for visualization of oesophageal mucosal pathology and may provide an effective
method to evaluate patients for oesophageal disease.
Following on from this initial landmark study a second generation esophageal capsule, ESO-
2, was released by Given Imaging in 2007 with a 30% increase in the frame capture rate from
14 to 18 frames per second, advanced optics with three lenses instead of one lens, and ex‐
pansion of field of view from 140◦ to 169◦.To maximize visualization of the EGJ and reduce
the presence of bubbles, the standardized ingestion protocol (SIP) was published by Gralnek
et al. [62] and included having the patient lie on his/her right side during capsule ingestion
while sipping 5–10 ml of water every 30 seconds. A subsequent clinical trial in 28 subjects
using the SIP protocol and ESO-2 demonstrated visualization of the Z-line in 75% of sub‐
jects, and sensitivity of 100% with specificity of 74% for BE detection. The agreement be‐
tween ESO-2 and EGD for description of the Z-line was 86% (k = 0.68).
A 2009 meta-analysis [63] including nine studies with 618 patients undergoing primarily the
first generation VCE demonstrated a pooled sensitivity and specificity of VCE for BE detection
of 77% and 86% compared to 78% sensitivity and 90% specificity for upper GI endoscopy.
9. ESS - Elastic Scattering Spectroscopy
Elastic scattering spectroscopy (ESS) is based on white light scattering. In ESS, photons hit
tissue and are backscattered without a change in wavelength. The relative intensity of this
backscattering is influenced by the composition of the interrogated tissue, specifically the
relative concentration of scatterers (i.e. nuclei, mitochondria, connective tissue) and absorb‐
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ers (i.e. hemoglobin). With the transition to dyplasia or neoplasia, tissues typically experi‐
ence an increase in nuclear crowding and enlargement and a change in biochemical
composition. All of these changes lead to characteristic alterations in light scattering, which
can be used to delineate different tissue types.
ESS spectra relate to the wavelength-dependence and angular-probability of scattering effi‐
ciency of tissue micro-components. The sizes, indices of refraction and structures of the
denser sub-cellular components (e.g., the nucleus, nucleolus, mitochondria) are known to
change upon transformation to premalignant or malignant conditions. Indeed, histopatholo‐
gists use these nuclear changes to grade dysplasia, i.e. the sizes and shapes of nuclei and or‐
ganelles, the ratio of nuclear to cellular volume (nuclear:cytoplasmic ratio) and clustering
patterns (nuclear crowding).
ESS is a point measurement. Mourant et al. analyzed elastic light scattering from isolated
mammalian tumor cells and nuclei [64]. Using cells at different stages of growth in the cell
cycle they demonstrated that light scattering at angles greater than about 110° was correlat‐
ed with the DNA content of these cells. Based on model calculations and the relative size
difference of nuclei from cells in different stages of growth, they suggest that this difference
in scattering results from changes in the internal structures of the nucleus that are increased
in the mitotic states.
In order to take optical measurements a flexible fibre-optic probe is passed down the work‐
ing channel of an endoscope and normal white light is shone at the underlying tissue for a
fraction of a second. The back-scattered light is collected and a spectral analysis performed.
This scattering of light is sensitive to changes in the structure of the underlying cells and has
already been shown to be able to detect HGD with a high degree of accuracy. Using pattern
recognition techniques such as multivariate discriminate analysis, algorithms have been de‐
veloped to classify spectra as premalignant or benign tissues. Optical measurements require
less than a second to collect and during the collection of over 10,000 readings in previous
studies no complications have occurred.
Our group at the National Medical Laser Centre at University College London have per‐
formed the largest clinical in vivo study of scattering spectroscopy to date, evaluating the
value of ESS in discriminating dysplastic and non-dysplastic tissue in Barrett’s esophagus
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[65]. A total of 181 matched biopsy sites from 81 patients, where histopathological consensus
was reached, were analysed. There was good pathologist agreement in differentiating high
grade dysplasia and cancer from other pathology (kappa = 0.72). Spectral data was analysed
by LDA + PCA to form a model which was then tested by leave one out cross validation (jac‐
knife analysis). Elastic scattering spectroscopy detected HGD or cancer with 92% sensitivity
and 60% specificity. If used to target biopsies during endoscopy, the number of low risk bi‐
opsies taken would decrease by 60% with minimal loss of accuracy. ESS had a negative pre‐
dictive value of 99.5% for high grade dysplasia or cancer. These novel and very promising
results show that ESS has the potential to target conventional biopsies in Barrett’s surveil‐
lance. In order to validate this technique, a prospective study is required.
10. Raman spectroscopy
The Raman effect was first discovered and described in 1928 by Chandrasekhar Venkata
Raman, for which he was awarded the Nobel Prize in 1930. It is an optical diagnostic techni‐
que that is a very valuable analytical tool. Only recently has it been used for biological and
medical research. It exploits the frequency shift, which occurs when a sample is illuminated
with laser light, due to the excitation of vibrational states in the constituent molecules. The
most significant characteristic of Raman spectra is that the intensity of the individual peaks
is linearly proportional to the concentration of the molecular constituents. Thus, a precise
molecular fingerprint is obtained. It is a rapid, non-destructive, optical scattering technique
that has the ability of objective identification of molecular markers such as protein confor‐
mation, nucleic acid and glycogen content. Thus the Raman spectrum is a direct function of
the molecular biology of the tissue. Extensive work has identified typical peaks, in the re‐
gion 900e1800 cm_1, seen in the normal esophageal epithelium that changes during the
process of malignant transformation. These may be useful for optical detection of neoplastic
transformation during endoscopy.
11. FTIR spectroscopy
FTIR spectroscopy is an analytical technique that is based on the absorption of light in the
region that excites molecular vibrations. Most spectrometers operate in the mid-IR range of
approximately 4000 to 900 cm-1. Molecular vibrations can be excited to higher levels by the
absorption of radiation in this range. Absorption occurs when the energy of the IR radiation
matches the energy difference of the 2 vibrational states. In this way, IR spectra gives infor‐
mation about the molecular vibrations in a given sample manifesting themselves in absorb‐
ance peaks at variable frequencies.
There is much literature outlining the success of FTIR spectroscopy in the identification of
cancerous tissues from normal tissue. Donna et al. [66] found specific spectral changes in the
Fourier Transform spectrum of esophageal cancers. Such changes were attributed to a range
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of molecular alterations such as the decrease in glycogen level and the increase in DNA con‐
tent. Limited work has however been done in the discrimination of the pre-malignant dys‐
plastic states of Barrett’s esophagus using FTIR spectroscopy.
In 2009 Wang et al. [67] studied the use of FTIR in tissue from patients with BE. In this series,
spectra were collected from 98 excised specimens of the distal oesophagus, including 38 squ‐
amous, 38 intestinal metaplasia (Barrett’s), and 22 gastric, obtained endoscopically from 32
patients. They demonstrated that DNA, protein, glycogen, and glycoprotein comprise the
principal sources of infrared absorption in the 950- to 1,800-cm-1 regime. The concentrations
of these biomolecules were quantified by using a partial least squares fit and used to classify
disease states with high sensitivity, specificity, and accuracy. Moreover, use of FTIR to de‐
tect premalignant (dysplastic) mucosa results in a sensitivity, specificity, positive predictive
value, and total accuracy of 92%, 80%, 92%, and 89%, respectively, and leads to a better in‐
ter-observer agreement between two gastrointestinal pathologists for dysplasia (K 0.72) ver‐
sus histology alone (K 0.52). This was the first study that demonstrated that the
concentration of specific biomolecules can be determined from the FTIR spectra collected in
attenuated total reflectance mode and can be used for predicting the underlying histopathol‐
ogy, which will contribute to the early detection and rapid staging of many diseases.
12. Virtual colonoscopy
Virtual colonoscopy (VC) is a diagnostic method enabling the generation of two- dimen‐
sional  and  three-dimensional  images  of  the  colon  and  rectum  from  the  data  obtained
with  relevant  imaging  modality,  usually  spiral  computed  tomography  (CT).  If  CT  is
used, the method is also called CT colonoscopy, CT colonography, or CT pneumocolon.
The main advantages of  the VC which support  its  broader application in medical  prac‐
tice include: limited invasiveness, improved compliance of patients and value for screen‐
ing for colorectal cancer.
The patient undergoing helical computed tomography with the intent of obtaining VC
should undergo complete bowel preparation as for other procedures within abdomen, e.g.
endoscopic colonoscopy. The priority is assigned to evacuation of the contents of the colon
before CT. For this purpose, many agents are used including ethylene glycol electrolyte sol‐
ution, magnesium citrate or oral sodium phosphate. Nevertheless, the quality of bowel
preparation for VC varies considerably between different centres (Van Uitert et al., 2008).
The trend for the optimization of the diagnostic procedures and limitation of the burden to
the patient resulted also in a strategy focusing on the performing of the optical colonoscopy
just after VC, if it is positive for pathological lesions in the colon, in order to avoid repetition
of the bowel preparation procedure. A strategy enabling identification of the artifacts result‐
ing from fecal contents in the bowel in the process of generation of VC images was also pro‐
posed. This is achieved by labeling it with some type of contrast agent, e.g. barium or
meglumine diatrizoate taken orally before the CT (Iannaccone et al., 2004).
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Growing use of the VC is supported by its lower invasiveness in the comparison to oth‐
er  diagnostic  procedures  and  potential  for  higher  compliance  from  patients.  These  fea‐
tures increase the value of  the techniques as a screening test  for disorders of  the colon.
The main indications  for  VC include screening for  colonic  polyps or  cancer  and failure
or inadequate results of optical colonoscopy due to anatomical conditions or pathological
lesions, e.g. obstruction of the colon lumen. Furthermore, the VC enables also for exami‐
nation of  extra-colonic  structures  not  accessible  during standard colonoscopy.  This  may
be particularly important  for  these patients  in whom pathological  lesions were detected
inside the colon lumen.
The Guidelines issued in 2008 by American Cancer Society, American College of Radiology
and US Multi-Society Task Force on Colorectal Cancer included VC within recommended
screening tests for colorectal cancer, which should be performed at 5 years intervals in pop‐
ulation of at least 50 years or older (Levin et al., 2008). According to the Guidelines, VC
should be performed after complete bowel preparation. The detection of a polyp of size >6
mm in VC necessitates the performance of optical colonoscopy, preferably the same day or
second complete bowel preparation is needed
12.1. Patient preparation for VC
The purpose of bowel preparation is to clean out the colon before imaging. Preparations
can  be  the  so-called  wet  preparations,  such  as  polyethylene  glycol  and  sodium  phos‐
phate preparations or the drier laxatives including magnesium citrate preparations,  fleet
enemas, bisacodyl tablets and LoSo Prep. Generally phospho-soda (fleet enema) is recom‐
mended  for  young  and  healthy  patients  while  the  polyethylene  glycol  preparation  is
preferable for the elderly.
Prepless techniques are currently also being investigated, requiring faecal tagging methods.
This is achieved by the use of orally ingested agents, usually dilute barium or iodinated con‐
trast medium that ‘tag’ or ‘label’ residual fluid or faecal matter.
A single dose of laxative together with three doses of 250 ml 2.1 % w/v barium sulphate the
day before the scan may equal diagnostic performance in fully pre- pared patients. Image
analysis requires a dedicated CT colonographic software package to ‘subtract’ the high at‐
tenuation labelled faecal residue from the colonic lumen, i.e. CT colonographic software
package with a subtraction capability.
12.2. Data acquisition
Thin-slice acquisition protocols with multi-detractor row CT to cover the entire abdomen in
a single breath hold should be used; 2.5 mm or 1.25 mm collimation is recommended.
12.3. Positioning
Scanning usually begins in the supine position and is subsequently performed in the prone
position if fluid is present in the colon. The second acquisition is to ensure that fluid-filled
segments can be interpreted later.




The efficacy of administering Buscopan or glucagon before scanning to improve colonic dis‐
tension is con- troversial. In a study of 240 patients who underwent virtual colonoscopy, Ro‐
galla and colleagues found that glucagon improved distension significantly only when the
results were analysed per segment; however Buscopan provided better volume distension
and sig- nificantly reduced the number of collapsed colonic segments.
12.5. Insufflation
Automated insufflation with carbon dioxide (CO2) using an automatic insufflation device is
recommended as this maintains a constant CO2 pressure during scan- ning. Where an auto‐
matic insufflator is not available, a hand pump may be used with insufflation of room air.
12.6. Low-dose CT
Intrinsic high contrast between the colonic wall and insufflated gas allows dose-saving low
MA protocols (e.g. 50 mAs). Recent data suggest that excellent sen- sitivity for cancer and
polyps of over 6 mm can be achieved using a collimation of 2.5 mm and tube cur- rent of 10
mAs giving an effective dose of 2.15 mSV in men and 2.75 mSV in women.
12.7. Intravenous contrast for problem solving
The use of contrast is also controversial in virtual colo- noscopy. A study performed by Mar‐
tina Morrin and colleagues foundthatsensitivityimprovedfrom58%to 75% with the use of IV
contrast. Intravenous contrast is helpful if there is poor preparation of the patient and
should be used as a problem-solving tool.
12.8. Interpretation of data
Interpretation  of  data  can  be  performed  by  a  3D  fly-  through  endoluminal  approach,
with  simultaneous  cor-  relation  with  2D  axial  images  and  2D  MPR  images,  soft-  ware
packages  which  include  multiple  imaging  layout  formats  for  adequate  visualisation  of
the entire colon.
As CT colonography becomes more widespread, there is increasing inter-observer variation
in interpretation. Computer-aided diagnosis (CAD) plays an important role in this regard.
When applied to the colon, CAD relies on three main steps: (i) extraction of the colon from
the 3D CT volume; (ii) identification of potential polyp candidates; and (iii) eliminating false
positives as far as possible.
12.9. Detection of lesions
In a study performed by Pickhardt et al. polyps greater than 6 mm were detectable using
1.25 – 2.5 mm col- limitation with multi-detector row CT. Sensitivity and specificity of CT
colonography decreases as lesion size decreases below 5 mm.
Medical Imaging in Clinical Practice164
The gastroenterological literature emphasizes the advanced adenoma as an appropriate tar‐
get for screening. The advanced adenoma is classified by size or histology, with lesions
greater than 10 mm or with villous histology being significant.
There has been debate about significance of small  lesions in CT colonography screening
or  surveillance  programmes;  however  practically  this  is  not  an  issue  for  endoscopic
screening techniques, as all lesions seen are removed. However with radiological screen‐
ing, Pickhardt et al. have considered a cut-off size of 8 mm or greater as a recommenda‐
tion  for  conventional  colonoscopy,  and  recommend  repeat  follow-up  scans  for  smaller
lesions after 2 – 3 years.
13. Endoscopic ultrasound (EUS)
EUS combines 2 modalities:  endoscopic visualization and high-frequency US. The ability
to image the wall of the GI tract as a series of definable layers corresponding to histolo‐
gy, rather than as a single entity, is the basis for most indications for EUS. Other indica‐
tions  have  emerged  from  the  ability  of  EUS  to  provide  detailed  images  of  areas  in
immediate proximity to the GI tract and to guide needles precisely through the gut wall
into surrounding structures.
The addition of endoluminal US offers a unique advantage over traditional endoscopy, al‐
lowing precise differentiation of the individual layers of the GI tract, and direct imaging of
the surrounding organs and tissue. EUS allows assessment of submucosal GI lesions, loco
regional staging of GI malignancy, tissue diagnosis, and staging of pancreaticobiliary le‐
sions, non small-cell lung carcinoma, and mediastinal disease. In prospective trials, EUS has
consistently been shown to have a significant impact on diagnosis and management. EUS-
guided FNA has emerged as an adjunctive modality during standard endosonography, al‐
lowing tissue diagnosis of submucosal lesions, extraluminal lesions, and/or lymph nodes.
Further- more, therapeutic uses for EUS have been described and are used on a limited basis
in some institutions.
EUS has become firmly established as an adjunctive endoscopic imaging study for patients
with previously identified lesions of the GI tract and surrounding organs. Multiple studies
suggest that EUS is superior to CT for tumor (T) and lymph node (N) staging of luminal and
pancreaticobiliary malignancies. The ultimate choice of staging modalities is largely depend‐
ent upon patient selection and local expertise.
13.1. The role of endoscopic ultrasound in staging of oesophageal cancer
Following on from a histological diagnosis of OAC it is imperative to complete a clinical
TNM staging. This has recently been changed in the American Joint Committee on Cancer
(AJCC) Seventh Edition.
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Table 1. 2011 AJCC 7th Edition TNM staging guidelines
The evidence suggests that EUS can successfully differentiate early (T1) from advanced in‐
tramucosal disease but it is poor at differentiating mucosal from submucosal lesions. Its role
in managing patients with early disease therefore appears to be limited, although it does ap‐
pear valuable for detecting associated malignant lymphadenpathy. Although the quality of
computed tomography (CT) and magnetic resonance imaging (MRI) images has improved
dramatically, EUS remains part of the standard algorithm for staging tumours [66;67].
Studies with small cohorts of cases have demonstrated that EUS can accurately predict sub‐
mucosal invasion, especially when lesions are examined with high frequency EYS probes
(20MHz) as this modality helps to delineate all 9 layers of the oesophagus compared to just
the conventional 5 layers as seen by normal resolution EUS. Furthermore the role of EUS
staging is limited by operator experience, location of the neoplasia and morphology of the
lesion (flat versus elevated versus depressed).
In the last  few years,  endoscopic  assessment of  patients  with early oesophageal  cancers
has come increasingly to rely on EMR to assess for  submucosal  invasion.  In a  prospec‐
tive  study  of  64  patients  by  the  Wiesbaden  group,  all  subjects  were  carefully  screened
with conventional radial EUS at a frequency of 7.5 MHz and with HFPUS if a visible le‐
sion was present [68].  Pre-EMR staging was in agreement with the histological  findings
in 58 of the 64 patients (91%) evaluated. Two cases of EUS tumor over stage and 4 cases
of EUS tumor downstage occurred.
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In the largest trial to date, a prospective blinded trial by the same group compared stag‐
ing of early oesophageal carcinoma using high resolution endoscopy (HR-E) with HFPUS
[69].  There was no significant difference in diagnostic  accuracy between the two techni‐
ques  (83%  for  HR-E  and  80%  for  HFPUS).  Sensitivity  for  mucosal  tumours  was  more
than  90%  for  both  modalities  while  sensitivity  for  submucosal  tumours  was  lower,  at
56% for  HR-E  and  48% for  HFPUS.  HFPUS was  significantly  more  accurate  at  staging
submucosal tumours in the tubular oesophagus (10/11; 91%) than those located at the oe‐
sophagogastric junction (2/14, 14%).
In a large study of 50 patients from Notingham by Thomas et al. [70] the role of EUS in de‐
tecting depth of invasion and nodal involvement was investigated in patients with early
Barrett’s associated neoplasia of the oesophagus. Visible lesions in the Barrett's segment
were described as Paris types 0-1 (n = 9), 0-IIb (n = 12), 0-IIa (n = 12), 0-IIa + IIc (n = 6), and 0-
IIc (n = 5). Of the 50 patients, 46 (92%) had either EMR (n = 17), oesophagectomy (n = 23), or
both (n = 6). All 12 patients (100%) with Paris 0-IIb lesions had T0/T1 m staging on EUS con‐
firmed with resection histology. The sensitivity for EUS T-staging for Paris classification was
71.4% for type 0-I, 100% for type 0-IIb, 83% for type 0-IIa, 66.7% for type 0-IIa + IIc, and
66.7% for type IIc. Overall, 8 (17%) of the 46 patients were under staged and 2 (4%) were
over staged. This study demonstrated that for detecting submucosal invasion, EUS has a
sensitivity of 66%, a specificity of 93%, a negative predictive value of 85%, and a diagnostic
accuracy of 84.4%.
14. Comparing EUS to CT and PET CT
EUS is also an important tool for evaluating malignant lymph nodes with a high sensitivity
and specificity. The ability of EUS to detect lymph node involvement has been compared to
computerised tomography (CT) in several studies. In a prospective study of 100 patients
with confirmed early cancer in BE, Pech et al. compared the two modalities for accuracy of
lymph node staging [71]. For the purposes of this study lymph nodes were considered as
non-malignant when the pathological assessment was negative or the long-term follow-up
showed no progression. EUS had a sensitivity of lymph node involvement of 75% and spe‐
cificity of 97%, compared to 38% sensitivity and 100% specificity for CT.
In a more recent series by Choi et al. [72] where a total of 109 patients with respectable OAC
were prospectively enrolled and retrospectively reviewed for evaluation of pre-operative
EUS,PET and CT. The study showed that the overall accuracy of EUS for T-staging was 72%,
and importantly it was the only method of delineating the oesophageal wall layers. The sen‐
sitivities for N staging were 42% for EUS, 49% for PET, and 35% for CT, and their specifici‐
ties were respectively, 9187 and 93%. The accuracy for N staging was 66% for EUS, 68% for
PET and 63% for CT, and it did not differ across the 3 diagnostic modalities. This series
shows that for loco-regional staging, EUS provides excellent T staging accuracy and similar
accuracy for N staging compared with PET and CT scanning.




There have been significant efforts in recent years towards improving the ability to make
real-time  pathological  diagnoses  during  endoscopy  of  the  upper  gastrointestinal  tract.
Decision making with respect to endoscopic treatment has been informed greatly as a re‐
sult,  meaning  therapy  can  be  delivered  without  delay  obviating  the  need  for  repeated
endoscopic procedures.
Practices  have  evolved greatly  from the  traditional  approach  of  WLE and non-targeted
biopsy.  Today  many  more  additional  techniques  are  available,  from  chromoendoscopy
and NBI to improved post- processing technology, through to the potential  of OCT and
ESS. These have prospective roles not only in detecting dysplasia in Barrett’s esophagus,
but also in the diagnosis and management of early esophageal squamous cell carcinoma
and adenocarcinoma.  The  introduction  of  virtual  colonoscopy with  high sensitivity  and
specificity will allow skilled endoscopists to focus their time on interventional procedure
and remove some of the growing burden of routine diagnostic colonoscopy. EUS contin‐
ues  to  use  the  established radiological  modalities  in  the  GI  tract  to  define  tissue  layers
and stage neoplastic diseases accurately.
The challenge remains to clarify the exact roles of these techniques in clinical practice, to
standardize their use (particularly with respect to classification systems) and to appropriate‐
ly incorporate them into clinical practice on a large scale.
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